U.S. Markets closed

BTG plc (BTG.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
664.000.00 (0.00%)
At close: 4:36PM BST
People also watch
HIK.LDPH.LRPC.LVEC.LELM.L

BTG plc

5 Fleet Place
London EC4M 7RD
United Kingdom
44 20 7575 0000
http://www.btgplc.com

Sector
Industry
Full Time Employees1,558

Key Executives

NameTitlePayExercisedAge
Dr. Dame Louise Makin MA, Ph.D.(Cantab), MBA, DBEChief Exec. Officer & Exec. Director1.61M3.86k56
Mr. Rolf Kristian Berndtson Soderstrom BA, ACACFO & Exec. Director981k9.65k51
Dr. Peter StratfordChief Technical Officer and Head of InnovationN/AN/A50
Dr. Melanie G. Lee CBE, Ph.D., FMedSci, DSc (Hons)Chief Scientific OfficerN/AN/A59
Mr. Andy BurrowsVP of Corp. and Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and interventional pulmonology products, including PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Specialty Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of envenomations from the copperhead snake; Vistogard for the treatment of 5-fluorouracil toxicity; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup for hip joint replacement; and Lemtrada for treatment of multiple sclerosis. The company also manufactures and commercializes therapeutic ultrasound devices. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom.

Corporate Governance

BTG plc’s ISS Governance QualityScore as of August 1, 2017 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.